Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...

Boston, USA-based biotech Solid Biosciences saw its shares rocket 36% to $5.48 yesterday, after the precision genetic ...

Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% ...

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

Solid Biosciences said Tuesday that the first three patients to receive its experimental gene therapy for Duchenne muscular dystrophy all produced high levels of microdystrophin, a miniature ...

best-in-class Duchenne muscular dystrophy gene therapy candidate — — Encouraging early signals of potential cardiac benefit observed — —SGT-003 has been well-tolerated in the 6 ...